NCT05292443 2024-02-23
Therapeutic ResistAnce and Clonal Evolution Assessed With Liquid Biopsy in ICIs Treated Primary Liver Cancer
Geneplus-Beijing Co. Ltd.
Withdrawn
Clinical Trials
4 trialsNCT03770299 2022-03-24
CheckMate 9TN
Bristol-Myers Squibb
Phase 2 Withdrawn
NCT03220009 2018-10-03
Nivolumab or Expectant Observation Following Ipilimumab, Nivolumab, and Surgery in Treating Patients With High Risk Localized, Locoregionally Advanced, or Recurrent Mucosal Melanoma
National Cancer Institute (NCI)
Phase 2 Withdrawn
NCT00411281 2015-09-30
Low-Dose Cytarabine in Treating Infants With Down Syndrome and Transient Myeloproliferative Disorder
Children's Oncology Group
Phase 3 Withdrawn